Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $5.43 Average Price Target from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned an average rating of “Hold” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $5.4286.

Several brokerages have recently weighed in on GOSS. HC Wainwright decreased their price objective on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Oppenheimer decreased their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Finally, Barclays lowered shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th.

Gossamer Bio News Roundup

Here are the key news stories impacting Gossamer Bio this week:

• Neutral Sentiment: Context: Gossamer is a clinical‑stage biotech focused on seralutinib for pulmonary hypertension; the company recently reported a quarterly EPS miss (reported ($0.21) vs. ($0.20) est.) and has a low market cap and depressed share price, factors that can amplify the impact of litigation news.
• Negative Sentiment: Multiple national plaintiff firms have launched investigations alleging securities‑law violations and encouraging investors who lost money to pursue claims—this increases litigation risk, potential legal costs, and distraction for management. Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
• Negative Sentiment: Glancy Prongay Wolke & Rotter announced an investigation and described alleged misstatements tied to the same timeframe—more firms pursuing claims increases chance of consolidated, high‑profile litigation. Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP
• Negative Sentiment: The Schall Law Firm is soliciting lead‑plaintiff candidates and reminding investors of an existing class action; lead‑plaintiff fights can prolong litigation and increase exposure. GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Berger Montague and several other national plaintiffs’ firms (e.g., Faruqi & Faruqi, DJS, Pomerantz, Robbins, Bronstein) have filed or publicized class actions/investigations; the broad participation signals potential for consolidated, costly litigation and settlement exposure. Berger Montague PC Investigating Claims on Behalf of Gossamer Bio, Inc. (GOSS) Investors After Class Action Filing
• Negative Sentiment: Faruqi & Faruqi and other firms are reminding investors of the June 1, 2026 lead‑plaintiff deadline—these reminders typically accelerate filings and media attention, keeping the company in the headlines and pressuring the share price. GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

Gossamer Bio Stock Performance

Shares of GOSS opened at $0.37 on Friday. The company has a 50-day simple moving average of $1.20 and a 200-day simple moving average of $2.26. Gossamer Bio has a 52 week low of $0.32 and a 52 week high of $3.87. The firm has a market capitalization of $86.84 million, a P/E ratio of -0.49 and a beta of 2.16.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $13.80 million during the quarter, compared to analyst estimates of $7.53 million. As a group, equities analysts forecast that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Trading of Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Legal & General Group Plc bought a new position in Gossamer Bio during the second quarter worth about $26,000. Ciovacco Capital Management LLC acquired a new stake in Gossamer Bio during the third quarter valued at approximately $27,000. Banco BTG Pactual S.A. bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $27,000. MMA Asset Management LLC acquired a new position in shares of Gossamer Bio in the 4th quarter worth approximately $31,000. Finally, Soltis Investment Advisors LLC acquired a new position in shares of Gossamer Bio in the 4th quarter worth approximately $31,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.